IS THERE A RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES (PROS) AND CLINICAL OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) POST-DOCETAXEL?

被引：2
|
作者：
Traina, S. [1 ]
Li, T. [1 ]
Johnson, K. [1 ]
Ho, K. F. [2 ]
Molina, A. [3 ]
Cella, D. [4 ]
机构：
[1] Janssen Res & Dev, Raritan, NJ USA
[2] STAT TU Inc, Toronto, ON, Canada
[3] Janssen Res & Dev, Menlo Pk, CA USA
[4] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1244
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN226
引用
收藏
页码：A470 / A470
页数：1
相关论文
共 50 条
  • [1] ANALYSIS OF THE RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES (PROS) AND CLINICAL OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS WITHOUT PRIOR CHEMOTHERAPY
    Traina, S.
    Li, T.
    Johnson, K.
    Ho, K. F.
    Molina, A.
    Cella, D.
    VALUE IN HEALTH, 2015, 18 (07) : A335 - A336
  • [2] Patient-reported outcomes in metastatic castration-resistant prostate cancer
    Fallowfield, Lesley
    Payne, Heather
    Jenkins, Valerie
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (10) : 643 - 650
  • [3] Patient-reported outcomes in metastatic castration-resistant prostate cancer
    Lesley Fallowfield
    Heather Payne
    Valerie Jenkins
    Nature Reviews Clinical Oncology, 2016, 13 : 643 - 650
  • [4] Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Petrylak, Daniel P.
    Ratta, Raffaele
    Matsubara, Nobuaki
    Korbenfeld, Ernesto Pablo
    Gafanov, Rustem
    Mourey, Loic
    Fer, Tilman Todenho Spacing Diaeresis
    Gurney, Howard
    Kramer, Gero
    Bergman, Andre M.
    Zalewski, Pawel
    De Santis, Maria
    Armstrong, Andrew J.
    Gerritsen, Winald R.
    Pachynski, Russell Kent
    Saretsky, Todd L.
    Ghate, Sameer R.
    Li, Xin Tong
    Schloss, Charles
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [5] Clinical activity of enzalutamide pre- and post-docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Nadal, Rosa
    Zhang, Zhe
    Raheja, Hitesh
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [6] PATIENT REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Aggarwal, S.
    Segal, J.
    Kumar, S.
    VALUE IN HEALTH, 2013, 16 (07) : A421 - A421
  • [7] Clinical activity of enzalutamide (Enza) pre- and post-docetaxel in teen with metastatic castration-resistant prostate cancer (mCRPC).
    Nadal, Rosa
    Zhang, Zhe
    Raheja, Hitesh
    Eisenherger, Mario A.
    Antonarakls, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Effect of abiraterone acetate (AA) on patient-reported pain in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel: Results of longitudinal sensitivity analyses.
    Hao, Yanni
    Cleeland, Charles S.
    Gagnon, Dennis
    Espindle, Derek
    Molina, Arturo
    Basch, Ethan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Patient Characteristics and Overall Survival (OS) in the Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer (mCRPC) Community Setting
    Cheng, Wendy Y.
    Miao, Raymond
    Duh, Mei Sheng
    Vekeman, Francis
    Sung, Jennifer
    Gauthier-Loiselle, Marjolaine
    Fortier, Jonathan
    Dhawan, Ravinder
    Oh, William K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 557 - 558
  • [10] Health-related quality of life (HRQoL) patient-reported outcomes (PROs) and survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)
    David, Lorente
    Lozano, Rebeca
    de Velasco, Guillermo
    Romero-Laorden, Nuria
    Castro, Elena
    Rodrigo-Aliaga, Miguel
    Sanchez, Angel L.
    Di Capua, Carlos
    Sanchez-Hernandez, Alfredo
    Olmos, David
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345